Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy

Inflammatory Bowel Diseases

Volumn 13, Issue 11, 2007, Pages 1379-1384

  Miheller, Pál ^a   Muzes, Györgyi ^a   Rácz, Károly ^a   Blázovits, Anna ^a   Lakatos, Péter ^a   Herszényi, László ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Bone mineral density; OPG concentration; RANKL

Indexed keywords

AZATHIOPRINE; CALCIUM; INFLIXIMAB; MESALAZINE; METHOTREXATE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTICLE; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; FEMALE; HUMAN; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BONE RESORPTION; CROHN DISEASE; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND;

EID: 36749098487     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20234     Document Type: Article

References (34)

1. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut. 1987;28:410-415.
2. Bjarnason I, Macpherson A, Mackhintos C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228-233.
3. Szathmári M, Prónai L, Tulassay Z. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol. 1998;93:848-849.
4. van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:1591-1597.
5. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors of bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol. 1999;94:824-828.
6. Sakellariou GT, Moschos J, Berberidis C, et al. Bone density in young males with recently diagnosed inflammatory bowel disease. Joint Bone Spine. 2006;73:725-728.
7. Bartram SA, Peaston RT, Rawlings DJ, et al. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J Gastroenterol. 2006;12:5680-5686.
8. Nanes MS. Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology. Gene. 2003;321:1-15.
9. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblasts differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141:3956-3964.
10. Azuma Y, Kaji K, Katogi R, et al. Tumor necrosis factor alpha-induces differentiation and bone resorption by osteoclasts. J Biol Chem. 2000;257:4858-4864.
11. Kaji K, Katogi R, Azuma Y, et al. Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J Bone Miner Res. 2001;16:1593-1599.
12. Tsuboi M, Kawakami A, Nakashima T, et al. Tumor necrosis factor-alpha and interleukin-1 beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med. 1999;134:222-231.
13. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun. 1999;256:449-455.
14. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
15. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869.
16. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
17. Korczowska I, Hrycaj P, Lacki JK. Does infliximab decrease bone turnover in rheumatoid arthritis patients [Letter]. Joint Bone Spine. 2003;70:398-400.
18. Korczowska I, Hrycaj P, Lacki JK. Change in biomarkers of osteoporosis in rheumatoid arthritis patients treated with infliximab. Pol Arch Med Wewn. 2004;111:637-638.
19. Vis M, Voskuyl AE, Wolbink GJ, et al. and the OSTRA Study Group. Bone mineral density in patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis. 2005;64:336-337.
20. Demis E, Roux C, Breban M, et al. Infliximab in spondylarthropathy - influence on bone density. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S185-186.
21. Bernstein M, Irwin S, Steinhart H, et al. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease [Abstract]. Gastroenterology. 2004;126(Suppl 2):S1420.
22. Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci. 2006;1068:543-556.
23. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol. 2006;40:55-63.
24. Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851-857.
25. Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm Bowel Dis. 2005;11:325-330.
26. Kanamaru F, Iwai H, Ikeda T, et al. Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells. Immunol Lett. 2004;94:239-246.
27. Meijer MJ, Mieremet-Ooms MA, van Duijn W, et al. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:200-210.
28. Nakamichi Y, Udagawa N, Kobayashi Y, et al. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol. 2007;178:192-200
29. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005;54:479-487.
30. Miheller P, Muzes G, Zagoni T, et al. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis. 2006;24:201-206.
31. Schoon EJ, van Nunen AB, Wouters RS, et al. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol. 2000;232:43-47.
32. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1895-1902.
33. Siffiledeen JS, Fedorak RN, Siminoski K, et al. Bones and Crohn's:risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis. 2004;10:220-228.
34. Stockbrugger RW, Schoon EJ, Bollani S, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther. 2002;16:1519-1527.